FDA weighs new application to approve MDMA as first-ever psychedelic medicine for PTSD
The MAPS Public Benefit Corporation (MAPS PBC) announced on Tuesday [12/12/23] that it submitted the new drug application (NDA) to FDA, requesting an expedited review given that the agency previously designated the psychedelic as a breakthrough therapy. If the NDA is ultimately approved, the Drug Enforcement Administration (DEA) would then need to reschedule MDMA accordingly.…
Recent Comments